Integra LifeSciences Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Integra LifeSciences (IART) Reports In-Line Q2 EPS, Revenues Miss; Boosts FY18 EPS/Revenue Mid-Point Outlooks Below Consensus
July 25, 2018 6:11 AM EDTIntegra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.60, in-line with the analyst estimate of $0.60. Revenue for the quarter came in at $366.2 million versus the consensus estimate of $368.25 million.
Revenue Increased 29.8% to $366.2 million; Organic Revenue Increased 3.4% Reported EPS of $0.14; Adjusted EPS of $0.60Raises Low-End of Full-Year Total Revenue and EPS GuidanceSuccessfully Exits First Wave of Codman Transition Services AgreementsSecond Quarter 2018 Consolidated Results
Reported revenue was $366.2 million, an increase of 29.8% compared to the second quarter of 2017;... More